FDA Approves Teva's Granix Injection For Self-Administration

(RTTNews) - Israeli drugmaker Teva Pharmaceutical Industries Ltd. (TEVA) said Tuesday that the U.S. Food and Drug Administration has approved Granix Injection for self-administration by patients and caregivers.

With the approval of the additional administration option, physicians will soon have the flexibility to prescribe Granix for either in-office or at home use.

Granix, a leukocyte growth factor, is indicated for reduction in the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Granix has been commercially available in the U.S. since November 2013. The currently marketed Granix syringe is indicated only for administration by a healthcare professional. Teva plans to launch a new Granix syringe, for self-administration by patients and caregivers, in early 2015.